An alternative TLR4 antagonist, CRX-526, blocks the ability of LPS, the natural ligand for TLR4 (208), to induce pro-inflammatory cytokines and improves both DSS and multidrug resistance gene 1a-deficient models of colitis (228). The gene discussed is TLR4; the disease is colitis.